Last reviewed · How we verify

Tau PET scan using MK-6240 — Competitive Intelligence Brief

Tau PET scan using MK-6240 (Tau PET scan using MK-6240) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Neurology.

phase 3 PET imaging agent Tau protein (paired helical filaments) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Tau PET scan using MK-6240 (Tau PET scan using MK-6240) — University of California, Irvine. MK-6240 is a positron emission tomography (PET) imaging agent that binds to tau protein aggregates in the brain to visualize tau pathology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tau PET scan using MK-6240 TARGET Tau PET scan using MK-6240 University of California, Irvine phase 3 PET imaging agent Tau protein (paired helical filaments)
Fluciclovine PET/CT Fluciclovine PET/CT OHSU Knight Cancer Institute marketed PET imaging agent Amino acid transporters (LAT1, ASCT2)
PET Scan with [18F] VAT PET Scan with [18F] VAT Stony Brook University marketed PET imaging agent / Radiopharmaceutical Vascular adhesion molecules (VAM)
[F-18]-Fludeoxyglucose [F-18]-Fludeoxyglucose University of Saskatchewan marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
Raclopride C11 Raclopride C11 University of North Carolina, Chapel Hill marketed Dopamine D2/D3 receptor antagonist (PET imaging agent) Dopamine D2 receptor, Dopamine D3 receptor
[Ga-68]PSMA [Ga-68]PSMA Norbert Avril, M.D. marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen)
[11C]raclopride [11C]raclopride New York State Psychiatric Institute marketed Dopamine D2/D3 receptor antagonist (PET imaging agent) Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

  1. University of California, San Francisco · 2 drugs in this class
  2. Central Hospital, Nancy, France · 1 drug in this class
  3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  5. Institute for Neurodegenerative Disorders · 1 drug in this class
  6. OHSU Knight Cancer Institute · 1 drug in this class
  7. Piramal Imaging Limited · 1 drug in this class
  8. SOFIE · 1 drug in this class
  9. Universidad Central del Caribe · 1 drug in this class
  10. University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tau PET scan using MK-6240 — Competitive Intelligence Brief. https://druglandscape.com/ci/tau-pet-scan-using-mk-6240. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: